SecSonar.com

Neurogene Inc. (NGNE)

Neurogene Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Neurogene Inc. (NGNE) is a Biotechnology company based in US with a market capitalization of $441.4M. Free cash flow was negative at -$78.4M. This page tracks NGNE's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 107 employees · IPO Mar 7, 2014

Valuation

Valuation & price

$29.82 · as of May 17, 2026 · -15.6% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

1.67

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$35.34$26.12$16.89Jul 25Dec 25Jul 26Jul 7, 25$19.50Jul 9, 25$21.26Jul 11, 25$21.43Jul 15, 25$21.47Jul 17, 25$22.60Jul 21, 25$21.66Jul 23, 25$23.09Jul 25, 25$22.72Jul 29, 25$21.00Jul 31, 25$21.77Aug 4, 25$21.72Aug 6, 25$21.29Aug 11, 25$20.35Aug 13, 25$21.11Aug 15, 25$20.51Aug 19, 25$19.71Aug 21, 25$19.75Aug 25, 25$19.98Aug 27, 25$19.70Aug 29, 25$18.48Sep 3, 25$19.87Sep 5, 25$19.95Sep 9, 25$19.25Sep 11, 25$20.08Sep 16, 25$17.44Sep 18, 25$18.68Sep 22, 25$16.98Sep 24, 25$17.25Sep 26, 25$17.82Sep 30, 25$17.33Oct 2, 25$20.98Oct 6, 25$23.09Oct 8, 25$25.83Oct 10, 25$30.21Oct 14, 25$33.20Oct 16, 25$33.99Oct 21, 25$31.57Oct 23, 25$28.71Oct 27, 25$32.06Oct 29, 25$32.67Oct 31, 25$34.26Nov 4, 25$31.80Nov 6, 25$26.66Nov 10, 25$28.30Nov 12, 25$31.08Nov 14, 25$22.77Nov 18, 25$21.36Nov 20, 25$20.40Nov 25, 25$20.74Nov 28, 25$21.08Dec 2, 25$19.24Dec 4, 25$21.16Dec 8, 25$20.59Dec 10, 25$20.76Dec 12, 25$20.92Dec 16, 25$19.53Dec 18, 25$19.28Dec 22, 25$20.85Dec 24, 25$20.07Dec 29, 25$20.14Jan 2, 26$20.16Jan 6, 26$18.30Jan 8, 26$18.68Jan 12, 26$17.28Jan 14, 26$18.80Jan 16, 26$17.55Jan 21, 26$18.31Jan 23, 26$18.31Jan 27, 26$19.87Jan 29, 26$18.89Feb 2, 26$18.33Feb 4, 26$17.18Feb 9, 26$17.62Feb 11, 26$16.89Feb 13, 26$17.38Feb 18, 26$17.21Feb 20, 26$17.64Feb 24, 26$18.90Feb 26, 26$19.68Mar 2, 26$20.74Mar 4, 26$23.91Mar 6, 26$22.17Mar 10, 26$23.07Mar 12, 26$22.30Mar 17, 26$21.08Mar 19, 26$19.19Mar 23, 26$19.36Mar 25, 26$22.03Mar 27, 26$20.35Mar 31, 26$20.16Apr 2, 26$20.69Apr 7, 26$20.91Apr 9, 26$21.37Apr 13, 26$19.28Apr 15, 26$24.00Apr 17, 26$27.85Apr 22, 26$27.27Apr 24, 26$27.03Apr 28, 26$27.45Apr 30, 26$26.09May 4, 26$28.22May 6, 26$32.33May 8, 26$30.78May 12, 26$31.54May 14, 26$31.27May 18, 26$27.98May 20, 26$26.95May 22, 26$27.71May 28, 26$27.50Jun 1, 26$27.54Jun 3, 26$26.22Jun 5, 26$26.49Jun 9, 26$28.81Jun 11, 26$29.00Jun 15, 26$29.86Jun 17, 26$30.79Jun 22, 26$32.25Jun 24, 26$30.07Jun 26, 26$32.03Jul 2, 26$35.34
$16.3752-week range$35.34
Loading valuation history…

Fundamentals

Key fundamentals

$441.4M

Market cap

—

Revenue growth (YoY)

-251.0%

Gross margin

-$78.4M

Free cash flow (USD)

-$259.1M

Net debt

Net cash position

20.5%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$0.00FY 2017$0.00FY 2018$25.0MFY 2019$0.00FY 2020$0.00FY 2021$0.00FY 2022$0.00FY 2023$0.00FY 2024$925.0KFY 2025$0.00
$0$0

Free cash flow by year

2016 → 2025

FY 2016$-30.9MFY 2017$-45.2MFY 2018$-31.6MFY 2019$-16.3MFY 2020$-26.8MFY 2021$-64.8MFY 2022$-55.1MFY 2023$-51.7MFY 2024$-71.4MFY 2025$-78.4M
-$30.9M-$78.4M

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

2

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 12, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $167K · 10b5-1 PlanCvijic Christine Mikail · Director, President and CFO · $166.6KJul 2, 2026Filing
  • 8-K eventPublic Offering AnnouncedJul 1, 2026Filing
  • 8-K eventPhase 1/2 Trial UpdateJun 29, 2026Filing
  • 8-K eventCorporate Presentation ReleasedJun 8, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 4, 2026Filing
  • Quarterly report10-Q FiledMay 12, 2026Filing
  • 8-K eventCorporate Presentation ReleasedMay 12, 2026Filing
  • Insider sellInsider Sell $300K · 10b5-1 PlanCvijic Christine Mikail · Director, President and CFO · $300KMay 8, 2026Filing
  • 8-K eventBoard Expansion and AppointmentsApr 20, 2026Filing

Questions

Frequently asked questions

What is Neurogene Inc.'s market cap?

Neurogene Inc. (NGNE) has a market capitalization of $441.4M.

What is NGNE's P/E ratio?

A meaningful P/E ratio is not available for NGNE — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is NGNE's price-to-book (P/B) ratio?

NGNE trades at 1.67 times book value per share.

Are insiders buying NGNE stock?

SEC Form 4 filings show no open-market insider buys at Neurogene Inc. in the last 90 days (2 sells).

Same arena

Related companies in Biotechnology

ASMB

Assembly Biosciences, Inc.

$441.9M

PRTC

PureTech Health plc

$439.4M

ADCT

ADC Therapeutics S.A.

$433.1M

DBVT

DBV Technologies S.A.

$454.8M

OCGN

Ocugen, Inc.

$470M

LYEL

Lyell Immunopharma, Inc.

$406.2M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.